CN1596951A - Phellodendron bark disperse tablet and its preparation method - Google Patents
Phellodendron bark disperse tablet and its preparation method Download PDFInfo
- Publication number
- CN1596951A CN1596951A CN 200410040343 CN200410040343A CN1596951A CN 1596951 A CN1596951 A CN 1596951A CN 200410040343 CN200410040343 CN 200410040343 CN 200410040343 A CN200410040343 A CN 200410040343A CN 1596951 A CN1596951 A CN 1596951A
- Authority
- CN
- China
- Prior art keywords
- cortex phellodendri
- dispersible tablet
- adjuvant
- weight
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A dispersing tablet of phellodendron bark is prepared from phellodendron bark and the medicinal auxiliary including microcrystalline cellulose, and carboxymethyl starch sodium and/or hydroxypropyl cellulose. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of damp-heat dysentery that is used for the treatment of, jaundice, leukorrhagia, pyretic stranguria, beriberi, flaccidity is soft, night sweat, seminal emission, skin infection swells and ache, the medicine of diseases such as damp and hot pruritus.Be the Chinese patent medicine of feedstock production with the Chinese herbal medicine specifically, the invention still further relates to the preparation method of this medicine.
Technical background
Gastroenteropathy and diseases of urinary system are variant, but the traditional Chinese medical science thinks that damp and hot causing a disease is an importance of its generation, and treating different diseases with the same therapeutic principle is an important principles of Chinese medical discrimination.
Cortex Phellodendri has heat clearing and damp drying, pathogenic fire purging removes the effects such as treating skin ulcer of steaming, detoxify, and being used to treat Chinese medical discrimination is damp and hot caused disease.Mainly containing alkaloid such as effective constituent berberine hydrochloride in the Cortex Phellodendri medical material has bacteriostasis, and the inflammation local vascular is had contraction, can alleviate the local inflammation reaction; Clinical Practice proof determined curative effect, toxic and side effects is little, is subjected to doctor and patient's favorable comment deeply; Beijing Tiantan Hospital's Digestive System Department finds that by the clinical observation on the therapeutic effect that adopts berberine hydrochloride treatment irritable bowel syndrome berberine hydrochloride has curative effect preferably to irritable bowel syndrome, and is particularly better to the effect of symptoms such as alleviation diarrhoea.
Cortex Phellodendri pharmaceutical preparation of the prior art is capsule, but have that dose is big, produce effects is slower etc. defective.
The content of invention
The objective of the invention is: on the basis of guaranteeing former Cortex Phellodendri capsule clinical efficacy, it is little to develop a kind of consumption, and produce effects is fast, and patient is easy to accept, and is convenient to preserve and carry stay-in-grade Cortex Phellodendri dispersible tablet.
Another object of the present invention provides the preparation method of this Cortex Phellodendri dispersible tablet therapeutic agent.
Solution of the present invention is on the basis of former Cortex Phellodendri capsule clinical efficacy, according to the physicochemical property of the main effective ingredient berberine hydrochloride of Cortex Phellodendri dispersible tablet, is index with extractum yield and berberine hydrochloride extraction ratio, determines to adopt optimization extraction process route; According to the galenic pharmacy principle, accessory formula is screened, be index with critical relative humidity and mouldability, investigated disintegrating agent, filler and granulation solvent and method of granulating, molding technological condition is investigated; And according to its effect and curing mainly, from antibiotic, antiinflammatory, analgesic, Expermental research on main pharmacodynamics has been carried out in 4 aspects of Immune Effects, and with former dosage form Cortex Phellodendri capsule relatively, simultaneously for investigating the safety of preparation, carried out the research of acute toxicity and long term toxicity test.
According to technique scheme, the medicament that the Cortex Phellodendri dispersible tablet that the present invention relates to is made up of following portions by weight proportion raw material Cortex Phellodendri and adjuvant thereof: wherein
Cortex Phellodendri 90～110 adjuvants 7.5～15
Described adjuvant be as the microcrystalline Cellulose of filler and as the carboxymethyl starch sodium of disintegrating agent or/and hyprolose; Ratio of weight and number between filler and the disintegrating agent is (1～3): (1～6).
The parts by weight ratio range of the formula optimization of preparation medicine of the present invention is:
Cortex Phellodendri 95～105 adjuvants 9～12
The optimum weight umber proportioning of medicine of the present invention is:
Cortex Phellodendri 100 adjuvants 10.
The preparation method of the Cortex Phellodendri dispersible tablet therapeutic agent that the present invention relates to is as follows:
1, get Cortex Phellodendri earlier, decoct with water 3～5 times, collecting decoction filters, and filtrate decompression is concentrated into half amount approximately;
2, in above-mentioned filtrate, add the calcium hydroxide of Cortex Phellodendri weight 1～3% 70～80 ℃ the time, stir evenly, be incubated 8～12 minutes, filtration while hot, filtrate decompression is condensed into the clear paste that relative density is 1.05～1.15 (60 ℃).Drying is collected xeraphium;
3, adjuvant is joined in the above-mentioned xeraphium in proportion, mixing is granulated in right amount with solvent, dry below 60 ℃, is pressed into tablet, promptly.
Above-mentioned granulation solvent is 75% alcoholic solution that contains 1～3% 30 POVIDONE K 30 BP/USP 3O.
An important feature of the present invention is to want the physicochemical property of effective ingredient berberine hydrochloride according to drug main, optimizes the extraction process route; Use efficient adjuvant, improved the stripping of Cortex Phellodendri effective ingredient berberine hydrochloride, have characteristics such as good dispersing state, disintegration time is short, the medicine stripping is rapid, absorption is fast, bioavailability is high, dose is little, onset is rapid, be convenient for carrying and take.
Medicine effect of the present invention is learned, the pharmaceutical research result shows, compares with original dosage form Cortex Phellodendri capsule, and following advantage is arranged:
1, present, dispersible tablet is mainly used in the chemicals field; Dispersible tablets of Chinese medicine is less relatively.
2, the Cortex Phellodendri dispersible tablet have stronger antibiotic, antiinflammatory, analgesic, regulate effect such as immunity, and be better than former dosage form Cortex Phellodendri capsule.
3, with the produced Cortex Phellodendri dispersible tablet of the inventive method, use efficient adjuvant, improved the stripping of Cortex Phellodendri effective ingredient berberine hydrochloride, have that good dispersing state, disintegration time are short, the medicine stripping rapidly, absorb fast, bioavailability is high, onset characteristics rapidly.
4, the Cortex Phellodendri dispersible tablet of indication of the present invention is compared with original dosage form Cortex Phellodendri capsule, both reduced volumes, reduce taking dose again, be convenient for carrying and take, can swallow, chew to contain and suck or after aqueous dispersion, take, especially the patient who is fit to old children and dysphagia the more important thing is that its drug effect is higher than original capsule when dosage reduces or be suitable.
5, the efficient adjuvant of described Cortex Phellodendri dispersible tablet application all plays quick disintegration in preparation, and can strengthen this bioavailability of medicament.
The specific embodiment
One, the selection of adjuvant test
1, the selection of disintegrating agent
Add identical adjuvant according to above ratio and granulate (adjuvant is a carboxymethyl starch sodium), tabletting is observed hygroscopicity and is surveyed disintegration time.
Disintegration time is measured: by " inspection requirements of dispersible tablet dispersing uniformity is carried out under 2000 editions two appendix IA tablets of the Chinese pharmacopoeia item, and 2 of dispersible tablets are placed 19～21 ℃ of water of 100ml, and its complete jitter time is write down in jolting.
Table 1 Cortex Phellodendri dispersible tablet molding prescription result of the test
Cortex Phellodendri: adjuvant granulation difficulty hygroscopicity disintegration time
100: 5 than difficulty strong＞3min
100: 10 easy weak＜3min
100: 20 than difficulty extremely weak＜3min
The result shows, is 100: 5 by Cortex Phellodendri/adjuvant, and the difficulty of granulating, hygroscopicity are difficult to solve, and are difficult to reach requirement disintegration; By Cortex Phellodendri/adjuvant is 100: 20, the difficulty of granulating, and the sheet of making is looser, is to extract processing at 100: 10 to granulate easily by Cortex Phellodendri/adjuvant, and disintegrate is good.
The starting point of dispersible tablet prescription design be make tablet meet behind the water the short as far as possible time (＜3min) in disintegrate for very little granule and form uniform suspension, therefore need adding relatively large high-quality disintegrating agent and suspensoid.
The molding key of dispersible tablet is to select excellent disintegrating agent, controls the key factor of its quality: the one, select suitable adjuvant for use, and the 2nd, the granularity of control medicine and adjuvant.
Under the situation of this prescription medicated powder and adjuvant proportions constant, the drug extract powder is directly added different disintegrating agents, to granulate, tabletting serves as to investigate index with the important indicator disintegration time of dispersible tablet, the results are shown in Table 2:
The screening of table 2 Cortex Phellodendri dispersible tablet disintegrating agent kind
Disintegrating agent hyprolose carboxymethyl starch sodium sodium carboxymethyl cellulose microcrystalline Cellulose starch
Disintegration time＞5 second＞2 minutes＞4 minutes＞5 minutes＞8 minutes
The result shows in five kinds of disintegrating agents, and is better with hyprolose, carboxymethyl starch sodium, three kinds of adjuvants of sodium carboxymethyl cellulose.
Carboxymethyl starch sodium is a fast disintegrant, the influence of 1%～2% pair of disintegrate is not obvious, 3%～7% has obviously accelerated disintegrate, 8%～10% has postponed disintegrate on the contrary, may be because produce due to the colloid substance after the carboxymethyl starch sodium partial hydrolysis, because drawing of carboxymethyl is moist, the prepared tablet of 6% above addition all has the obvious moisture absorption, deliquescing phenomenon.And carboxymethyl starch sodium is put the easy moisture absorption in the air; Hyprolose has intensive hydrophilic, and this specific character can make tablet have withered knot performance in pressing process; Carmethose tool hygroscopicity.
Selection result of the test at disintegrating agent shows: the effect of hyprolose, carboxymethylstach sodium, carmethose is best, and the consumption that uses has separately all reached more than 54%, and tablet is can disintegrate rapid, but compacting back gained gets tablet hygroscopicity is arranged all, the tablet surface color deepens (moisture absorption) and gets trend.
Hyprolose (A), carboxymethyl starch sodium (B), sodium carboxymethyl cellulose (C) are surveyed disintegration time all with the mutual compatibility of equivalent, the results are shown in Table 3:
The screening of table 3 disintegrating agent compatibility
Disintegrating agent A+B A+C B+C A+B+C
30 seconds ≈ of 12 seconds ≈ of 10 seconds ≈ of disintegration time ≈ 35 seconds
The result shows: best with hyprolose (A)+carboxymethyl starch sodium (B) combination.
More than test shows, adds any disintegrating agent and can make the quick disintegrate of tablet, discharges fully, improves bioavailability of medicament, and best with hyprolose (A)+carboxymethyl starch sodium (B) combination.
2, the selection of filler
In order to reduce the moisture absorption of extract powder, be convenient to granulate and the used in amounts that reduces disintegrating agent will add certain filler, by following test, the results are shown in Table 4:
The screening of table 4 filler
The micropowder silica gel of filler pregelatinized Starch mannitol microcrystalline Cellulose
15 seconds ≈ of 3 minutes ≈ of 4 minutes ≈ of disintegration time ≈ 35 seconds
The result shows: microcrystalline Cellulose (MCC) is better than other filler.
3, the screening test of proportioning between the adjuvant
After determining supplementary product kind, ratio therebetween is bigger to the disintegration time influence, after the investigation, must the results are shown in Table 5
The screening (carboxymethyl starch sodium, hyprolose, microcrystalline Cellulose) of table 5 Cortex Phellodendri dispersible tablet adjuvant ratio
Adjuvant ratio 3: 2: 11: 3: 22: 1: 31: 1: 1
30 seconds ≈ of 35 seconds ≈ of 25 seconds ≈ of disintegration time ≈ 16 seconds
The result shows that carboxymethyl starch sodium: hyprolose: microcrystalline Cellulose is 1: 1: 1 o'clock optimum.
Two, the controlled trial of drug effect
For showing that medicine of the present invention has improved bioavailability, strengthened drug effect.Medicine of the present invention is raw material with the Cortex Phellodendri, carboxymethyl starch sodium, microcrystalline Cellulose are adjuvant and (carboxymethyl starch sodium: microcrystalline Cellulose=2: 1) make, study test group through mouse test main pharmacodynamics experiment from antibiotic, antiinflammatory, aspect contrived experiment such as analgesic: take medicine of the present invention; Matched group: take the original capsule medicine.Method and result are as follows:
1, adopt the interior antibacterial experiment of body to observe its protective effect to mouse infection escherichia coli Escherichia and staphylococcus aureus.
Table 6 Cortex Phellodendri dispersible tablet is to the influence of mice time-to-live of ehec infection Escherichia
Group dosage number of animals survival number death toll mortality rate
(g/kg) (only) (only) (only) (%)
Blank group 10 19 90
In the dispersible tablet 2.67 10 64 40
Former dosage form is high by 5.33 10 55 50
Ciprofloxacin 0.5 10 82 20
*
Annotate: compare with the blank group
*P＜0.05;
*P＜0.01.The result shows by table 6: test group is taken the effect (p＜0.05) of ehec infection survival rate in the opposing mice body that is significantly improved behind the Cortex Phellodendri dispersible tablet of the present invention, and taking dose has reduced half than former dosage and effect is better than former dosage form.
Table 7 Cortex Phellodendri dispersible tablet is to the influence of the time-to-live of infection staphylococcus aureus mice
Group dosage number of animals survival number death toll mortality rate
(g/kg) (only) (only) (only) (%)
Blank group 10 19 90
Dispersible tablet is high by 5.33 10 73 30
*
High 5.33 10 55 50 acetylspiramycins 0.4 10 82 20 of former dosage form
*
Annotate: compare with the blank group
*P＜0.05;
*P＜0.01.
The result shows by table 7: the obviously interior effect of infecting (p＜0.05) of protective money Staphylococcus aureus body of Cortex Phellodendri dispersible tablet high dose group is higher than former dosage form with dosage comparison Cortex Phellodendri dispersible tablet drug effect.
Table 8 Cortex Phellodendri dispersible tablet is to the influence of mouse peritoneal capillary permeability (X ± SD)
Group animal (only) dosage (g/kg) absorbance (OD)
Blank group 10 1.150 ± 0.255
In the dispersible tablet 10 2.67 0.668 ± 0.288
*
Former dosage form is high by 10 5.33 0.882 ± 0.180
Dexamethasone 10 0.005 0.854 ± 0.272
*
Annotate: compare with the blank group
*P＜0.05;
*P＜0.01
The result shows by table 8: the mouse peritoneal capillary permeability that the Cortex Phellodendri dispersible tablet can obviously suppress due to the acetic acid increases (p＜0.01), and taking dose has reduced half than former dosage and effect is better than former dosage form.
Table 9 Cortex Phellodendri dispersible tablet causes the influence (X ± SD) of rat paw edema to Ovum Gallus domesticus album
Before dosage causes inflammation
Cause scorching back swelling degree (ml)
Group
g/kg (ml) 30m 60m 120m 240m
Blank group 1.35 ± 0.09 0.87 ± 0.17 1.12 ± 0.18 1.09 ± 0.16 1.01 ± 0.18
In the sheet 2.67 1.41 ± 0.08 0.64 ± 0.16
*0.74 ± 0.19
*0.66 ± 0.15
*0.60 ± 0.23
In former dose 2.67 1.50 ± 0.12 0.80 ± 0.23 0.91 ± 0.21 0.95 ± 0.16 0.89 ± 0.20
Dexamethasone 0.005 1.34 ± 0.06 0.37 ± 0.23
*0.42 ± 0.14
*0.38 ± 0.06
*0.37 ± 0.08
*
Annotate: compare with the blank group
*P＜0.05;
*P＜0.01
The result shows by table 9: the Cortex Phellodendri dispersible tablet can obviously suppress the rat paw edema (p＜0.01～0.05) that Ovum Gallus domesticus album causes, and is higher than former dosage form with dosage comparison Cortex Phellodendri dispersible tablet drug effect.
Table 10 Cortex Phellodendri extract is to the influence of mice granuloma induced by implantation of cotton pellets (X ± SD)
Group number of animals dosage granuloma weight granulation ponderal index (mg/
(only) be (mg) 10g (g/kg))
Blank group 10 47.79 ± 7.87 19.02 ± 3.39
Dispersible tablet is high by 10 5.33 33.61 ± and 7.54 12.98 ± 2.79
*
In the dispersion 10 2.67 39.67 ± 8.60 14.62 ± 2.97
*
Former dosage form is high by 10 5.33 42.39 ± and 9.12 17.27 ± 2.37
In the former dosage form 10 2.67 51.37 ± 12.79 20.54 ± 4.63
Dexamethasone 10 0.005 27.95 ± 5.73 10.89 ± 2.55
*
Annotate: compare with the blank group
*P＜0.05;
*P＜0.01
The result shows by table 10: the Cortex Phellodendri dispersible tablet can obviously suppress form (p＜0.01) of mice granuloma induced by implantation of cotton pellets, compares the Cortex Phellodendri dispersible tablet with dosage and is better than former dosage form; Taking dose has reduced half than former dosage and effect is better than former dosage form.
3, by to 2,2, 4-dinitrophenol causes the influence of rat fever and yeast extract is caused the power that its refrigeration function is observed in the influence of rat fever.
Table 11 Cortex Phellodendri dispersible tablet is to 2, and 2, 4-dinitrophenol causes the influence (X ± SD) of rat fever
Fervescence value after the modeling of group dosage modeling precursor (℃)
The g/kg temperature (℃) 0.5h 1h 1.5h 2h 2.5h 3h
Blank group 36.80 ± 0.43 1.14 ± 0.07 1.36 ± 0.15 1.37 ± 0 44 1.19 ± 0.24 1.13 ± 0.26 1.15 ± 0.27
In the dispersion 2 37.19 ± 0.29 0.74 ± 0.24 0.75 ± 0.35
*0.64 ± 0.21
*0.63 ± 0.40
*0.46 ± 0.22
*0.43 ± 0.26
*
In former dose 2 37.43 ± 0.62 1.18 ± 0.16 1.47 ± 0.16 1.35 ± 0.19 1.25 ± 0.25 1.21 ± 0.24 1.24 ± 0.19
Asprin 0.1 37.12±0.26 0.39±0.13
**?0.64±0.12
** 0.62±0.08
**?0.57±0.14
**?0.50±0.11
**?0.46±0.15
**
Annotate: compare with the blank group
*P＜0.05;
*P＜0.01
The result shows by table 11: the Cortex Phellodendri dispersible tablet can obviously suppress 2, and rat temperature that 2, 4-dinitrophenol causes raises (p＜0.01) and is better than former dosage form with the dosage Cortex Phellodendri dispersible tablet of comparing.
4, its gastric infusion acute toxicity is little, does not measure LD
50. it is 64g crude drug in whole/Kg/ day that Cortex Phellodendri dispersible tablet extractum liquid Cmax, maximum volume are given gastric infusion amount of mice, be adult's (60Kg) consumption per day (0.267g crude drug in whole/Kg/ day) 240 times, show that Cortex Phellodendri disperses extract powder gastric infusion acute toxicity little, degree of safety is big.Cortex Phellodendri dispersible tablet 16,8, long-term (one month) administration of 4g crude drug in whole/kg do not have influence to the weight of animals growth, behavioral activity, peripheral hemogram, blood biochemical, organs and tissues etc.2 weeks, also no abnormality seen are observed in drug withdrawal.
Studies show that by above pharmacology and toxicology test: the Cortex Phellodendri dispersible tablet has stronger antibiotic, antiinflammatory, effect such as analgesic, and is better than Cortex Phellodendri capsule.Its gastric infusion acute toxicity is little, does not measure LD
50, it is 64g crude drug in whole/Kg/ day that Cortex Phellodendri dispersible tablet extractum liquid Cmax, maximum volume are given gastric infusion amount of mice, is 240 times of adult's (60Kg) consumption per day (0.267g crude drug in whole/Kg/ day).(January) administration does not for a long time have obviously influence to the weight of animals growth, behavioral activity, peripheral hemogram, blood biochemical, organs and tissues etc.2 weeks, also no abnormality seen are observed in drug withdrawal.Illustrate by clinical sign and use that the Cortex Phellodendri dispersible tablet is safe.
Four, the embodiment of production method
Embodiment 1.
Take by weighing raw material by following proportioning (by weight):
Cortex Phellodendri 100 adjuvants (microcrystalline Cellulose: carboxymethyl starch sodium=1: 1) 10
Production method is as follows:
Get Cortex Phellodendri, decoct with water four times, add 10 times of amounts of water for the first time, second and third, add 8 times of amounts of water for four times, each 30 minutes, collecting decoction filtered, filtrate decompression is concentrated into half amount approximately, and the adding Cortex Phellodendri is measured 2% calcium hydroxide in the time of 80 ℃, stirs evenly, and is incubated 10 minutes, filter while hot, filtrate decompression is condensed into the clear paste of relative density about 1.10 (60 ℃), and drying is collected xeraphium, add adjuvant, mixing is granulated in right amount with 75% alcoholic solution that contains 30 POVIDONE K 30 BP/USP 3O, dry below 60 ℃, compacting is in blocks, promptly.
Embodiment 2.
Take by weighing raw material by following proportioning (by weight):
Cortex Phellodendri 100 adjuvants (microcrystalline Cellulose: hyprolose=1: 1) 10
Production method is as follows:
Get Cortex Phellodendri, decoct with water four times, add 10 times of amounts of water for the first time, second and third, add 8 times of amounts of water for four times, each 30 minutes, collecting decoction filtered, filtrate decompression is concentrated into half amount approximately, and the adding Cortex Phellodendri is measured 2% calcium hydroxide in the time of 80 ℃, stirs evenly, and is incubated 10 minutes, filter while hot, filtrate decompression is condensed into the clear paste of relative density about 1.10 (60 ℃), and drying is collected xeraphium, add adjuvant, mixing is granulated in right amount with 75% alcoholic solution that contains 30 POVIDONE K 30 BP/USP 3O, dry below 60 ℃, compacting is in blocks, promptly.
Embodiment 3.
Take by weighing raw material by following proportioning (by weight):
Cortex Phellodendri 100 adjuvants (microcrystalline Cellulose: carboxymethyl starch sodium: hyprolose=1: 1: 1) 10
Production method is as follows:
Get Cortex Phellodendri, decoct with water four times, add 10 times of amounts of water for the first time, second and third, add 8 times of amounts of water for four times, each 30 minutes, collecting decoction filtered, filtrate decompression is concentrated into half amount approximately, and the adding Cortex Phellodendri is measured 2% calcium hydroxide in the time of 80 ℃, stirs evenly, and is incubated 10 minutes, filter while hot, filtrate decompression is condensed into the clear paste of relative density about 1.10 (60 ℃), and drying is collected xeraphium, add adjuvant, mixing is granulated in right amount with 75% alcoholic solution that contains 30 POVIDONE K 30 BP/USP 3O, dry below 60 ℃, compacting is in blocks, promptly.
Claims (8)
1, a kind of Cortex Phellodendri dispersible tablet is characterized in that the medicament that it is made up of following portions by weight proportion raw material Cortex Phellodendri and adjuvant thereof: wherein
Cortex Phellodendri 90～110 adjuvants 7.5～15
Described adjuvant be as the microcrystalline Cellulose of filler and as the carboxymethyl starch sodium of disintegrating agent or/and hyprolose; Ratio of weight and number between filler and the disintegrating agent is (1～3): (1～6).
2, according to the described Cortex Phellodendri dispersible tablet of claim 1, it is characterized in that: the parts by weight proportioning was between raw material Cortex Phellodendri and adjuvant thereof were formed:
Cortex Phellodendri 95～105 adjuvants 9～12.
3, according to the described Cortex Phellodendri dispersible tablet of claim 1, it is characterized in that: the parts by weight proportioning was between raw material Cortex Phellodendri and adjuvant thereof were formed:
Cortex Phellodendri 100 adjuvants 10.
4, according to the described Cortex Phellodendri dispersible tablet of claim 1, it is characterized in that: adjuvant adopts carboxymethyl starch sodium, hyprolose, microcrystalline Cellulose, and its ratio of weight and number is 1: 1: 1.
5, according to the described Cortex Phellodendri dispersible tablet of claim 1, it is characterized in that: adjuvant adopts microcrystalline Cellulose, carboxymethyl starch sodium, and its ratio of weight and number is 1: 1.
6, according to the described Cortex Phellodendri dispersible tablet of claim 1, it is characterized in that: adjuvant adopts microcrystalline Cellulose, hyprolose, and its ratio of weight and number is 1: 1.
7 one kinds prepare the method for Cortex Phellodendri dispersible tablet according to claim 1, and it is characterized in that: step is as follows:
(1), earlier get Cortex Phellodendri, decoct with water 3～5 times, collecting decoction filters, and filtrate decompression is concentrated into half amount approximately;
(2), in above-mentioned filtrate, add the calcium hydroxide of Cortex Phellodendri weight 1～3% 70～80 ℃ the time, stir evenly, be incubated 8～12 minutes, filtration while hot, filtrate decompression is condensed into the clear paste of relative density about 1.05～1.15 (60 ℃).Drying is collected xeraphium;
(3), adjuvant is joined in the above-mentioned xeraphium in proportion, mixing is granulated in right amount with solvent, dry below 60 ℃, is pressed into tablet, promptly.
8, the method for preparing the Cortex Phellodendri dispersible tablet according to claim 7 is characterized in that: described granulation solvent is 75% alcoholic solution that contains 1～3% 30 POVIDONE K 30 BP/USP 3O.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100403437A CN100341539C (en) | 2004-07-30 | 2004-07-30 | Phellodendron bark disperse tablet and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100403437A CN100341539C (en) | 2004-07-30 | 2004-07-30 | Phellodendron bark disperse tablet and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1596951A true CN1596951A (en) | 2005-03-23 |
| CN100341539C CN100341539C (en) | 2007-10-10 |
Family
ID=34664615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100403437A Expired - Fee Related CN100341539C (en) | 2004-07-30 | 2004-07-30 | Phellodendron bark disperse tablet and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100341539C (en) |
-
2004
- 2004-07-30 CN CNB2004100403437A patent/CN100341539C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100341539C (en) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1872279A (en) | Composition of medication for treating ulcer in the oral cavity, and preparation method | |
| CN1768800A (en) | Chinese medicinal formulation for treating blennorrhagia and urinary system infection, and preparation method thereof | |
| CN1915216A (en) | New usage of tandospirone and its derivative, and composition containing tandospirone | |
| CN1966001A (en) | Medicament for treating inflammation and preparation method thereof | |
| CN100341539C (en) | Phellodendron bark disperse tablet and its preparation method | |
| CN101028329A (en) | Production and use for phyllanthin dispersing tablet preparation | |
| CN1615844A (en) | Development of micro particle silybum marianum preparation | |
| CN1850241A (en) | Dispersible tablet of Vitamin C and Lonicera and Forsythia and preparing method thereof | |
| CN1857574A (en) | Deafness treating Tongqiao Preparation and its preparing process | |
| CN1824208A (en) | Medicinal preparation for treating urticaria and its new preparation method | |
| CN1891266A (en) | Chinese medicine oral disintegrating tablet for treating angina pectoris, and its preparing method | |
| CN1891256A (en) | Red sage root dispersible tablet for treating cornary heart diseae and its preparing method | |
| CN1293895C (en) | Oral disintegration tablet for laryngopathy and its preparing method | |
| CN1307977C (en) | Propolis dripping pills for treating toothache and its preparation method | |
| CN1833666A (en) | Herba Andrographitis chewing tablets and prepn. method | |
| CN101066252A (en) | Aminoglucose calcium tablet and its prepn process | |
| CN1679673A (en) | Isatis root drops and preparation thereof | |
| CN1281272C (en) | Interferon effervescence capsule for vagina used and its preparation method | |
| CN1883603A (en) | Compound Chinese medicinal preparation for treating toothache and method for preparing same | |
| CN1626207A (en) | Preparation including unique ingredient and fabricating method | |
| CN1562210A (en) | Burnet disintegration tablet of mouth and preparation method | |
| CN1682817A (en) | Throat dripping pill for clearing away heat and toxic material and its preparing method | |
| CN1562060A (en) | Haw leaf total flavone oral disintegration tablet and its preparing method | |
| CN1679675A (en) | Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof | |
| CN100349601C (en) | Chinese proprietary medicine for treating arthritis, its preparation and quality control method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 400020 Chongqing city Hechuan Industrial Park Hill Road No. 168 Chongqing hilan Pharmaceutical Co Ltd Patentee after: Tang Dejiang Address before: 400020 Chongqing Jiangbei District, building a new East Road, hung Cheng Building, block B, building 8, building 33 Patentee before: Tang Dejiang |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071010 Termination date: 20160730 |